INTERCURE LTD. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 999.9 ILa | +0.77% |
|
+5.81% | +115.91% |
| 04-01 | InterCure Ltd. Provides Earnings Guidance for the Second Half and Full Year of 2023 | CI |
| 03-22 | InterCure Ltd. Expects to Launch Its First Products in Germany in the Coming Months | CI |
| Sales 2021 | 219.68 82.63K 17.53K | Sales 2022 | 388.68 146K 31.01K | Capitalization | 551M 207B 43.93B |
|---|---|---|---|---|---|
| Net income 2021 | 4M 1.5B 319M | Net income 2022 | 44M 16.55B 3.51B | EV / Sales 2021 | 3,844,919 x |
| Net cash position 2021 | 87.64M 32.96B 6.99B | Net Debt 2022 | 22.37M 8.41B 1.78B | EV / Sales 2022 | 1,473,908 x |
| P/E ratio 2021 |
207
x | P/E ratio 2022 |
12.2
x | Employees | 370 |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 64.2% |
More Fundamentals
* Assessed data
More news
Latest transcript on InterCure Ltd.
More press releases
| 1 day | +0.77% | ||
| 1 week | +5.81% | ||
| Current month | +1.31% | ||
| 1 month | +4.70% | ||
| 3 months | +114.76% | ||
| 6 months | +126.22% | ||
| Current year | +115.91% |
1 week
956.00
1 006.00
1 month
879.901 049.00
Current year
440.001 049.00
1 year
395.001 049.00
3 years
395.002 845.00
5 years
395.004 827.45
10 years
124.586 317.95
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 53 | 30/09/18 | |
Amos Cohen
DFI | Director of Finance/CFO | 45 | 29/02/20 |
Boaz Lahav
SAM | Sales & Marketing | - | 31/10/22 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Ehud Barak
CHM | Chairman | 81 | 31/08/18 |
| Chief Executive Officer | 53 | 30/09/18 | |
| Director/Board Member | 62 | 31/10/20 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 13.29% | 3 M€ | -35.65% | - | |
| 0.13% | 13 M€ | -.--% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 25/04/24 | 999.9 | +0.77% | 161,024 |
| 24/04/24 | 992.3 | +5.01% | 104,493 |
Delayed Quote TEL AVIV STOCK EXCHANGE, April 25, 2024 at 12:24 pm
More quotes
InterCure Ltd is an Israel-based company primarily enagged in cannabis industry. Thorugh its wholly owned subsidiary Canndoc the Company operates as licensed cannabis producer and one of the first to offer Good Manufacturing Practices (GMP) certified and pharmaceutical-grade medical cannabis products.
Calendar
12/05/2024
- Q1 2024 Earnings Release (Projected)
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +115.91% | 119M | |
| +31.96% | 272M | |
| +33.74% | 261M | |
| +49.42% | 194M | |
| +44.98% | 131M | |
| -28.57% | 121M | |
| -42.17% | 119M | |
| 0.00% | 86.82M | |
| +150.00% | 75.33M | |
| +1.20% | 55.24M |
- Stock Market
- Equities
- INCR Stock
